NetworkNewsWire
Editorial Coverage: Approximately 1,300 people die every day as a result of
smoking, and more than 16 million Americans are living with a
disease caused by smoking. These alarming numbers aren’t going
unnoticed, and companies with expertise in the space are seizing
the opportunity to provide solutions designed to help smokers kick
the habit. One of those companies, Kaival Brands
Innovations Group Inc. (OTCQB: KAVL) (KAVL
Profile), has just acquired a patent
covering the creation of all synthetic nicotine smoking cessation
and synthetic nicotine addiction therapy products; the company is
also creating a subsidiary that will own the patent and develop all
related products. The maker of Nicorette(R), GlaxoSmithKline PLC (NYSE: GSK)
creates innovative nicotine replacement therapies and smoking
cessation products, including the Nicorette(R) product line.
Perrigo
Company PLC (NYSE: PRGO) offers a healthy
lifestyle product portfolio that includes a full range of oral
nicotine products designed to help smokers kick the habit or cut
down on tobacco use. Altria
Group (NYSE: MO) has created QuitAssist(R), an online
resource to help smokers who are trying to quit be more successful.
And Reynolds American Inc., owned by British
American Tobacco Industries (NYSE: BTI), has a Tobacco
Harm Reduction ("THR") campaign designed to reduce the risks faced
by adult tobacco smokers by providing them with accurate
information tobacco and smoking.
- Seven million people die every year from tobacco use; 16
million Americans live with smoking-caused disease.
- Kaival Brands recently acquired a patent to create cessation
products using a specialized formulation of purified synthetic
nicotine that is tobacco-free.
- Kaival Labs Inc., a wholly owned subsidiary of KAVL, owns the
patented science and develops associated products.
Click here to view
the custom infographic of the Kaival Brands Innovations Group Inc.
(OTCQB: KAVL) editorial.
The Disturbing Numbers
Smoking is the leading cause of preventable death in the world
today. Worldwide, 7 million people die every year from tobacco use,
and the number is projected to increase to 8 million if the pattern
of smoking doesn’t change. In addition, smoking also leads to
disease and disability and harms nearly every organ of the body.
The Centers for Disease Control and Prevention reports that more
than 16 million Americans have a disease caused by smoking,
including cancer, heart disease, stroke, lung disease, diabetes,
chronic obstructive pulmonary disease, and more.
And all of this can be prevented.
The need to address these disturbing statistics is urgent, and
the potential benefits of doing so may include more than saving
lives. According to a Global Smoking Cessation Market Analysis
2019, the smoking cessation market is projected to reach $63.99 billion by 2026, growing at a CAGR of 16.9%
during 2018 to 2026.
The study defines smoking cessation as the process of
discontinuing tobacco smoking and includes products such as chewing
gum, inhalers, lozenges, patches, sprays and sublingual tablets and
therapies such as nicotine replacement therapy ("NRT"), non-NRT
therapy and e-cigarettes.
Effective and Satisfying, Yet Addiction
Free
Despite the threat of death and disease, the latest numbers from
the National Health Information Survey show that 34.2 million U.S. adults still smoke.
Approximately 70% of current adult smokers in the country want to
quit; in fact, 55% have attempted to quit in the past year. But the
success rate for kicking the habit is only 7% because nicotine is a
highly addictive chemical, and cigarettes are designed to deliver
that molecule quickly.
Kaival Brands
Innovations Group Inc. (OTCQB: KAVL), a company focused on
growing and incubating innovative and profitable products into
mature, dominant brands, is committed to making a difference in the
smoking cessation sector. The company, which has has reported
$54.8 million in
revenue and $6.9 million in gross profits thus far this year,
recently acquired an international patent portfolio concerning full
customization of certain isomeric properties of synthetic nicotine.
This Tobacco-Free Nicotine ("TFN") does not contain any trace of
tobacco; rather it is created from a natural starter that undergoes
several chemical reactions until it produces the desired
product.
"The science behind these patents has discovered that within the
nicotine molecule, the S-isomers control the addictive properties,
whereas the R-isomers control the beneficial qualities of the
nicotine that a user enjoys,” explained Kaival Brands CEO Niraj
Patel. “The exclusivity is that the patents allows us to control
the specific ratios of each isomer in the final synthetic nicotine
molecule we produce for cessation products. We can now create
completely unique products for smoking cessation and nicotine
addiction therapy that remain effective and satisfying for the
user, but are free from nicotine’s addictive traits.”
Creating a Tobacco-Free Future
In conjunction with the patent, Kaival Brands has announced the
creation of Kaival Labs
Inc., a wholly owned subsidiary, that will own the patent and
develop associated products.
“Kaival Labs will own the patented science to create a pure, yet
non-addictive synthetic nicotine for the development and production
of smoking cessation and nicotine replacement therapy products,”
said Patel. “Tobacco-Free Nicotine ('TFN') is a certified clean,
pure, non-tobacco-derived synthetic nicotine, and a key ingredient
in numerous products like nicotine patches, lozenges, gums, vape
sticks, e-liquids and more.”
Focused on pioneering the movement in creating a tobacco-free
future, Kaival Labs is committed to using research and science to
develop smoking cessation treatment options that help millions of
people quit cigarettes and improve public health through the
gradual eradication of nicotine addiction.
True Step-Down Products
Currently the majority of smoking cessation products or Nicotine
Reduction Therapy ("NRT") products are largely ineffective, simply
decreasing the concentrations of nicotine until users themselves
reduce their usage over time. This approach may have a lower
success rate because many users struggle with their cravings and
the additional withdrawal symptoms they experience when they try to
phase down.
Kaival Labs’ newly acquired patent allows the lab to control the
levels of each isomer in a final product, thereby producing
patented, true step-down products that reduce nicotine addiction
levels without reducing the benefits a user is used to.
The R-S- isomeric ratio in nicotine accounts for the addictive
and beneficial properties and strengths of the chemical. Kaival
Labs’ exclusive NRT formulation modifies the ratio of R- S-
isomers, resulting in synthetic nicotine that is effective in
curbing nicotine addiction and may even have potential for use on a
medical level in most beneficial form.
“Billions of smokers and tobacco users worldwide are looking for
an answer and a real solution to their nicotine addiction
problems,” said Patel. “Imagine patent-protected products, either
approved pharmaceutically or made available over-the-counter, that
offered a way to truly ease a user off their addictive cravings for
nicotine without losing any of their accustomed benefits along the
way. We are excited to develop these innovative patents and bring
effective, enjoyable smoking cessation products to market, helping
all nicotine users lead healthier and higher-quality lives.”
In a market with a desperate need for solutions, Kaival Brands
seems particularly well positioned to experience substantial growth
in a space that offers huge potential.
Supporting Efforts to Quit
Given that potential, it’s not surprising that other companies
are jostling for product market share and offering support in
smokers’ efforts to quit.
With a reputation for being at the forefront of NRT, GlaxoSmithKline PLC (NYSE: GSK)
offers a line of Nicorette
products, including the Nicorette Coated Ice Mint Lozenge, the
first and only FDA-approved coated lozenge. The line launched in
the Unites States in 1984 and was the world's first nicotine
replacement therapy. GSK also offers the NicoDerm CQ nicotine patch
in the United States, which initially launched in 1991. In 1996,
the FDA changed the status of Nicorette(R) Gum and NicoDerm CQ to
over-the-counter medicines, allowing millions of Americans easier
access to smoking cessation support.
Perrigo
Company PLC (NYSE: PRGO) offers a Nicotine Replacement Therapy ("NRT") portfolio of
products that includes NiQuitin and a private label proposition.
Both offerings feature a diverse range of products including
patches, lozenges and gums in different strengths designed to help
consumers quit their smoking addiction. The company’s private-label
NRT products can be found across the retail marketplace in
virtually all OTC retail stores as well as online.
Altria
Group’s (NYSE: MO) Quit Assist online
resource was developed with a review board of smoking cessation
experts. The program highlights the Centers for Disease Control and
Prevention's Five Keys for Quitting information and also helps
connect adult tobacco users who have decided to quit to expert
quitting information from public health authorities and others. A
major feature of the program includes success stories shared by
former smokers who have successfully quit.
British
American Tobacco Industries (NYSE: BTI) owns Reynolds
American Inc., which has a Tobacco Harm
Reduction ("THR") campaign that focuses on providing accurate
information about, and instituting regulatory policies that
reflect, the comparative risks between cigarettes and
noncombustible tobacco products and nicotine replacement therapies.
That information may encourage smokers who are unable or unwilling
to quit tobacco to consider switching to tobacco products that
present lower risks.
With an eye on lowering the number of deaths and disease related
to smoking as well as providing effective products and solutions in
the smoking cessation sector, companies with experience and
resources have much to offer.
For more information about Kaival Brands, please visit Kaival Brands
Innovations Group Inc. (OTCQB: KAVL).
About NetworkNewsWire
NetworkNewsWire
(“NNW”) is a financial news and content distribution company, one
of 40+ brands within the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a full
array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024